New study tracks treprostinil use in newborns with lung condition
NCT ID NCT06499363
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study will follow 60 newborns with persistent pulmonary hypertension (PPHN) who receive treprostinil as part of their routine care. Researchers will collect data on how the drug is used, its safety, and its effectiveness in real-world hospital settings. The goal is to better understand treatment patterns and outcomes for these fragile infants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- treprostinil
- What this could lead to
- If this study succeeds, it could provide valuable information on how treprostinil is used in real-world practice for newborns with pulmonary hypertension, potentially guiding better treatment decisions.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. The small size (60 participants) and lack of a comparison group limit the strength of conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT PULMONARY HYPERTENSION OF NEWBORN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Lille - Clinique de Néonatalogie
RECRUITINGLille, 59000, France
-
CHU Lyon (HCL) - Hopital Femme Mère Enfant
RECRUITINGBron, 69500, France
-
CHU de Toulouse Hopital des enfants - Réanimation Néonatale
RECRUITINGToulouse, 31300, France
-
Réanimation néonatale CHU Grenoble Alpes - Hôpital Couple Enfant
RECRUITINGGrenoble, 38043, France